Automate Your Wheel Strategy on OCGN
With Tiblio's Option Bot, you can configure your own wheel strategy including OCGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol OCGN
- Rev/Share 0.0163
- Book/Share 0.0105
- PB 96.6423
- Debt/Equity 10.7546
- CurrentRatio 1.828
- ROIC -1.4845
- MktCap 315428050.0
- FreeCF/Share -0.1791
- PFCF -6.0309
- PE -5.1801
- Debt/Assets 0.6124
- DivYield 0
- ROE -2.5525
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | OCGN | Maxim Group | -- | Buy | -- | $4 | Oct. 15, 2024 |
News
Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants
Published: August 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
MALVERN, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the closing of its previously announced registered direct offering pursuant to a securities purchase agreement with Janus Henderson Investors, a global asset management firm, for the purchase and sale of 20,000,000 shares of common stock and warrants to purchase up to an aggregate of 20,000,000 shares of common stock at a purchase price of $1.00 per share (closing price on August 7, 2025) and accompanying warrant. The warrants have an exercise price …
Read More
Ocugen, Inc. (OCGN) Q2 2025 Earnings Call Transcript
Published: August 01, 2025 by: Seeking Alpha
Sentiment: Neutral
Ocugen, Inc. (NASDAQ:OCGN ) Q2 2025 Earnings Conference Call August 1, 2025 8:30 AM ET Company Participants Arun Upadhyay - Chief Scientific Officer and Head of Research & Development Huma Qamar - Chief Medical Officer Ramesh Ramachandran - Chief Accounting Officer, Principal Financial Officer & Principal Accounting Officer Shankar Musunuri - Co-Founder, CEO & Chairman Tiffany J. Hamilton - AVP & Head of Corporate Communications Conference Call Participants Boris Peaker - Unidentified Company Daniil V.
Read More
Ocugen (OCGN) Reports Q2 Loss, Misses Revenue Estimates
Published: August 01, 2025 by: Zacks Investment Research
Sentiment: Negative
Ocugen (OCGN) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.04 per share a year ago.
Read More
Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team
Published: July 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
MALVERN, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced updates to its Retina Scientific Advisory Board (SAB) and Executive Leadership Team to enhance external guidance from key opinion leaders and strengthen the Company's internal expertise in critical functions and as it pursues its goal of three BLAs in the next three years.
Read More
Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results
Published: July 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
MALVERN, Pa., July 17, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to discuss the Company's second quarter 2025 financial results and provide a business update at 8:30 a.m. ET on Friday, August 1, 2025.
Read More
Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases
Published: June 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
PHILADELPHIA and MALVERN, Pa., June 23, 2025 (GLOBE NEWSWIRE) -- Carisma Therapeutics Inc. (Nasdaq: CARM) (Carisma) and OrthoCellix, Inc. (OrthoCellix), a wholly-owned subsidiary of Ocugen, Inc. (Nasdaq: OCGN) (Ocugen), a clinical-stage company developing regenerative cell therapies for orthopedic diseases, today jointly announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on the development of OrthoCellix's NeoCart® technology for the treatment of knee articular cartilage defects and plans to initiate a U.S. Food and Drug Administration (FDA)-endorsed Phase 3 clinical trial for NeoCart®.
Read More
Ocugen, Inc. Announces Signing of Binding Term Sheet for the License of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea
Published: June 05, 2025 by: GlobeNewsWire
Sentiment: Neutral
MALVERN, Pa., June 05, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the signing of a binding term sheet to negotiate and enter into a licensing agreement with a well-established leader in the pharmaceutical and healthcare sector in Korea, for exclusive Korean rights to OCU400—Ocugen's novel modifier gene therapy for retinitis pigmentosa (RP).
Read More
Ocugen, Inc. (OCGN) Q1 2025 Earnings Call Transcript
Published: May 09, 2025 by: Seeking Alpha
Sentiment: Neutral
Call Start: 8:30 January 1, 0000 8:59 AM ET Ocugen, Inc. (NASDAQ:OCGN ) Q1 2025 - Earnings Conference Call May 9, 2025, 8:00 AM ET Company Participants Tiffany Hamilton - Head, Corporate Communications Shankar Musunuri - Chairman, Chief Executive Officer & Co-Founder Ramesh Ramachandran - Chief Accounting Officer Huma Qamar - Chief Medical Officer Arun Upadhyay - Chief Scientific Office Conference Call Participants Michael Okunewitch - Maxim Group Robert LeBoyer - Noble Swayampakula Ramakanth - H.C. Wainwright Operator Good morning, and welcome to Ocugen's First Quarter 2025 financial results and business update.
Read More
Ocugen Provides Business Update with First Quarter 2025 Financial Results
Published: May 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
Conference Call and Webcast Today at 8:30 a.m. ET OCU400 Phase 3 clinical trial for retinitis pigmentosa (RP) is progressing well and on target for potential BLA/MAA filings by mid-2026 Anticipate initiating OCU410ST Phase 2/3 pivotal confirmatory clinical trial for Stargardt disease mid- 2025 MALVERN, Pa.
Read More
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress
Published: April 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform, including OCU400 for the treatment of retinitis pigmentosa (Phase 3 LiMeliGhT clinical trial), OCU410ST for the treatment of Stargardt disease (Phase 2/3 pivotal confirmatory clinical trial), and OCU410 for the treatment of geographic atrophy (Phase 2 ArMaDa clinical trial), at The Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting at the Calvin L. Rampton Salt Palace Convention …
Read More
Ocugen, Inc. (OCGN) Q4 2024 Earnings Call Transcript
Published: March 05, 2025 by: Seeking Alpha
Sentiment: Neutral
Ocugen, Inc. (NASDAQ:OCGN ) Q4 2024 Earnings Conference Call March 5, 2025 8:30 AM ET Company Participants Tiffany Hamilton - Head, Corporate Communications Shankar Musunuri - Chairman, Chief Executive Officer & Co-Founder Ramesh Ramachandran - Chief Accounting Officer Huma Qamar - Chief Medical Officer Conference Call Participants Michael Okunewitch - Maxim Group Swayampakula Ramakanth - H.C. Wainwright Robert LeBoyer - Noble Capital Markets Daniil Gataulin - Chardan Operator Good morning, and welcome to Ocugen's Fourth Quarter and Full Year 2024 Financial Results and Business Update.
Read More
Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
MALVERN, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that alignment has been reached with the U.S. Food and Drug Administration (FDA) to move forward with a Phase 2/3 pivotal confirmatory clinical trial for OCU410ST which, if positive, can be the basis of a biologics license application (BLA) submission.
Read More
Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results
Published: February 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
MALVERN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that it will host a conference call and live webcast to discuss the Company's fourth quarter and full year 2024 financial results and provide a business update at 8:30 a.m. ET on Wednesday, March 5, 2025.
Read More
Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
MALVERN, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that dosing is complete, ahead of schedule in the Phase 2 portion of the Phase 1/2 ArMaDa clinical trial for OCU410—a novel multifunctional modifier gene therapy candidate being developed for geographic atrophy (GA), an advanced stage of dry age-related macular degeneration (dAMD). Age-related macular degeneration (AMD) affects 1 in 8 people 60 years and older. The global prevalence of dAMD is 266 million worldwide and …
Read More
About Ocugen, Inc. (OCGN)
- IPO Date 2014-12-03
- Website https://www.ocugen.com
- Industry Biotechnology
- CEO Shankar Musunuri
- Employees 95